National Allergy Centre of Excellence: Ledger

Stories naming National Allergy Centre of Excellence. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
National Allergy Centre of Excellence is not recorded as having acquired anything.

Series B $66m

Aravax Media Release

Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.

Breakthrough Victoria 23 Jan 2024 Aravax Alfred Health National Allergy Centre of Excellence Agati Capital Brandon Capital Breakthrough Victoria Novartis Venture Fund Tenmile Uniseed UniSuper Grant Dooley Professor Jennifer Rolland Dr Pascal Hickey Professor Robyn O'Hehir Dr Sara Prickett

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)

National Allergy Centre of Excellence

Funding history

Investors

What National Allergy Centre of Excellence bought

People

Coverage

Aravax Media Release